Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protein for treatment of inflammatory diseases

An inflammatory disease and protein technology, applied in the field of lectin protein, can solve the problems of high demand, low output, and difficulty in buying

Active Publication Date: 2021-08-20
UNICHEM LAB LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The reason is that its price is high and it is difficult to buy due to low production volume and high demand

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein for treatment of inflammatory diseases
  • Protein for treatment of inflammatory diseases
  • Protein for treatment of inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0141] A study was carried out to evaluate the effect of a recombinant lectin having the amino acid sequence of SEQ ID NO: 2 on the secretion of inflammatory cytokines (IL-8 and IL-6) in a human synovial cell line (SW982). Recombinant lectins have the effect of inhibiting the secretion of inflammatory cytokines in cell lines.

[0142] Human synoviocytes (SW982) were first cultured for 24 hours, serum starved for 6 hours, and then the recombinant lectin with the amino acid sequence of SEQ ID NO: 2 and the inflammatory stimulus were used according to the non-toxic concentration of cells (1ng / ml-1,000ng / ml) (100 ng / ml IFN-γ) treated cells for 24 hours. The levels of cytokines (IL-6 and IL-8) in the supernatant were measured by ELISA. The inhibitory effect of recombinant lectins on cytokine secretion was calculated as follows:

[0143] Cytokine inhibition percentage=[(A-B) / A]*100

[0144] In the formula:

[0145] A = concentration of cytokines in control cells (IFN-γ only)

...

example 2

[0149] Another study was conducted to determine the effect of recombinant lectin having the amino acid sequence of SEQ ID NO: 2 on the secretion of inflammatory cytokines (TNF-α and The role of IL-1-β).

[0150] Spleen cells were isolated from C57BL / 6 mice and treated with recombinant lectin having the amino acid sequence of SEQ ID NO: 2 and lipopolysaccharide (LPS) at 25 ng / ml at a nontoxic concentration (1ng / ml-1,000ng / ml) 48 hours.

[0151] RAW264.7 cells were cultured for 24 hours, serum starved for 24 hours, and then the recombinant lectin with the amino acid sequence of SEQ ID NO: 2 and the inflammatory stimulus IFN-γ ( 100ng / ml) combined treatment of cells for 24 hours. The levels of cytokines (TNF-α and IL-1-β) in the supernatant were measured by ELISA.

[0152] The inhibitory effect of recombinant lectins on cytokine secretion was calculated as follows:

[0153] Cytokine inhibition percentage=[(A-B) / A]*100

[0154] In the formula:

[0155] A = concentration of c...

example 3

[0160] Another study was performed to determine the effect of a recombinant lectin having the amino acid sequence of SEQ ID NO: 2 on bone turnover markers (alkaline phosphatase (ALP) and collagen) in a human osteoblast cell line (MG-63). MG-63 cells were cultured for 24 hours, serum starved for 24 hours, and then treated with recombinant lectin having the amino acid sequence of SEQ ID NO: 2 at a nontoxic concentration (1 ng / ml-1,000 ng / ml) for 5 days. ALP activity in cell lysates was determined by the PnPP (p-nitrophenyl phosphate) method. Collagen levels in cell lysates were determined by Sircoll staining. The recombinant lectin having the amino acid sequence of SEQ ID NO: 2 can increase ALP activity (11%-42.8%) and collagen level (3.2%-45.3%) in a human osteoblast cell line (MG-63).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The lectin may comprise an amino acid sequence having sequence of SEQ ID NO: 1 or at least 60% homology to SEQ ID NO: 1.

Description

[0001] This application claims the benefit of Indian Provisional Patent Application No. 201821009667 filed on September 16, 2018, the entire contents of which are incorporated herein by reference. 【Technical field】 [0002] The present invention relates to a lectin protein, especially a lectin protein for preventing, treating and curing inflammation, including inflammatory diseases. 【Background technique】 [0003] Inflammation initiates the healing process by triggering a multifactorial chemical signaling network that protects injured tissue from further infection. This process involves the activation and migration of important blood cells (neutrophils, monocytes, and eosinophils) to the site of damage. Cells (macrophages, mast cells, endothelial cells, and Schwann cells) secrete cytokines and specific growth factors that promote nerve regeneration and eventually reestablish a normal microenvironment. [0004] Inflammation associated with wound healing (normal inflammation)...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16C07K14/47A61P19/02A61P29/00
CPCC07K14/4726A61K38/16A61P29/00A61P19/02A61K38/00A61K38/178
Inventor 达南杰·萨特苏迪普·库玛尔马马塔·卡特代尔
Owner UNICHEM LAB LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com